The initial Sport versions to include both work station and patient cart are “precursors” for the systems to be built for the trials next year, Toronto-based Titan said.
“This fully integrated initial EV system represents the efforts of many people at Titan, our surgeon advisory board and our development contractors. This is a major accomplishment for Titan as we move toward our 1st-in-human trials,” clinical & regulatory affairs executive vice president Dennis Fowler said in prepared remarks.
“I am very pleased and excited that we are able to finish off the year with such a positive accomplishment. I would encourage readers to visit our web site at www.titanmedicalinc.com where we have posted pictures of this complete initial Sport surgical system,” added chairman & CEO John Hargrove.
It’s been a busy season for Titan, which last week licensed “know-how and certain technology” from Mayo Clinic for the Sport device. In November the company inked an instrument development deal with Cadence Device, raised $4 million and $8.6 million in separate rounds, and signed a private placement deal with a subsidiary of Chinese medical device distributor Ningbo Long Hengtai International Trade Co. that could wind up being worth more than $24 million.